These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 2519317)

  • 41. The prophylaxis of seasickness. A comparison of cinnarizine with hyoscine.
    Hargreaves J
    Practitioner; 1982 Jan; 226(1363):160. PubMed ID: 7043439
    [No Abstract]   [Full Text] [Related]  

  • 42. Effect of drugs in altering susceptibility to motion sickness in aerobatics and the slow rotation room.
    Deane FR; Wood CD; Graybiel A
    Aerosp Med; 1967 Aug; 38(8):842-5. PubMed ID: 6049246
    [No Abstract]   [Full Text] [Related]  

  • 43. [Therapeutic considerations on kinetoses].
    Ferrotti A
    Minerva Med; 1970 Apr; 61(28):1408-16. PubMed ID: 4396663
    [No Abstract]   [Full Text] [Related]  

  • 44. Theory of antimotion sickness drug mechanisms.
    Wood CD; Graybiel A
    Aerosp Med; 1972 Mar; 43(3):249-52. PubMed ID: 4402925
    [No Abstract]   [Full Text] [Related]  

  • 45. Hope for the queasy.
    US Navy Med; 1976 Nov; 67(11):1-2. PubMed ID: 1076899
    [No Abstract]   [Full Text] [Related]  

  • 46. (--)-Hyoscine and cyclizine as motion sickness remedies.
    Brand JJ; Colquhoun WP; Gould AH; Perry WL
    Br J Pharmacol Chemother; 1967 Aug; 30(3):463-9. PubMed ID: 4860708
    [No Abstract]   [Full Text] [Related]  

  • 47. Pharmacological interventions for motion sickness: cardiovascular effects.
    Sunahara FA; Farewell J; Mintz L; Johnson WH
    Aviat Space Environ Med; 1987 Sep; 58(9 Pt 2):A270-6. PubMed ID: 3499896
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Influence of transdermal scopolamine on motion sickness during 7 days' exposure to heavy seas.
    van Marion WF; Bongaerts MC; Christiaanse JC; Hofkamp HG; van Ouwerkerk W
    Clin Pharmacol Ther; 1985 Sep; 38(3):301-5. PubMed ID: 4028625
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Effect of experimental motion sickness on postrotatory nystagmus and the illusion of counterrotation].
    Aĭzikov GS; Kliushnikova ON
    Kosm Biol Aviakosm Med; 1985; 19(2):89-91. PubMed ID: 3990240
    [No Abstract]   [Full Text] [Related]  

  • 50. Cycloplegia from transdermal scopolamine.
    Chiaramonte JS
    N Engl J Med; 1982 Jan; 306(3):174. PubMed ID: 7054664
    [No Abstract]   [Full Text] [Related]  

  • 51. INM investigations into drugs for seasickness prophylaxis.
    Pingree BJ
    J R Nav Med Serv; 1994; 80(2):76-80. PubMed ID: 7707278
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mechanisms of antimotion sickness drugs.
    Wood CD; Manno JE; Wood MJ; Manno BR; Redetzki HM
    Aviat Space Environ Med; 1987 Sep; 58(9 Pt 2):A262-5. PubMed ID: 3675502
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Scopolamine alone or combined with ephedrine in seasickness: a double-blind, placebo-controlled study.
    Laitinen LA; Tokola O; Gothoni G; Vapaatalo H
    Aviat Space Environ Med; 1981 Jan; 52(1):6-10. PubMed ID: 7011299
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of sixteen anti-motion sickness drugs under controlled laboratory conditions.
    Wood CD; Graybiel A
    Aerosp Med; 1968 Dec; 39(12):1341-4. PubMed ID: 4881887
    [No Abstract]   [Full Text] [Related]  

  • 55. [The role of cholinergic mechanisms in altering the functional activity of the rabbit brain during motion sickness].
    Maksimuk VF; Skoromnyĭ NA
    Fiziol Zh SSSR Im I M Sechenova; 1988 Aug; 74(8):1109-19. PubMed ID: 3197853
    [No Abstract]   [Full Text] [Related]  

  • 56. Scopolamine patch to prevent seasickness: clinical response vs. plasma concentration in sailors.
    Gil A; Nachum Z; Dachir S; Chapman S; Levy A; Shupak A; Adir Y; Tal D
    Aviat Space Environ Med; 2005 Aug; 76(8):766-70. PubMed ID: 16110693
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug treatment of motion sickness: scopolamine alone and combined with ephedrine in real and simulated situations.
    Tokola O; Laitinen LA; Aho J; Gothoni G; Vapaatalo H
    Aviat Space Environ Med; 1984 Jul; 55(7):636-41. PubMed ID: 6466260
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Transdermally administered scopolamine.
    Paasuke RT
    CMAJ; 1985 Nov; 133(10):956. PubMed ID: 4063911
    [No Abstract]   [Full Text] [Related]  

  • 59. FPIN's Clinical Inquiries. Treatment of motion sickness.
    Sutton M; Mounsey AL; Russell RG
    Am Fam Physician; 2012 Jul; 86(2):192-5. PubMed ID: 22962932
    [No Abstract]   [Full Text] [Related]  

  • 60. The efficacy of hyoscine hydrobromide in reducing side-effects induced during immersion in virtual reality.
    Regan EC; Ramsey AD
    Aviat Space Environ Med; 1996 Mar; 67(3):222-6. PubMed ID: 8775399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.